Home › Trial NCT03314740
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
- Trial IDNCT03314740
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorMario Negri Institute for Pharmacological Research
- Enrollment123
- Start date2017-06-12
- ConditionsOvarian Neoplasms
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.